Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis
摘要:
Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620. Analogues were optimized for the immunomodulatory activity and selectivity versus other TLRs, based on differential induction of key cytokines including interferon a (IFN-alpha) and tumor necrosis factor a (TNF-alpha). In addition, physicochemical properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties. GS-9620 is currently in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.
Provided are modulators of TLRs of Formula II:
pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
提供了公式II的TLR调节剂:其药用盐,含有这类化合物的组合物,以及包括给予这类化合物的治疗方法。
Modulators of toll-like receptors
申请人:Gilead Sciences, Inc.
公开号:US10172860B2
公开(公告)日:2019-01-08
Provided are modulators of TLRs of Formula II:
pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
所提供的是式 II 的 TLR 调节剂:
其药学上可接受的盐、含有此类化合物的组合物以及包括施用此类化合物的治疗方法。
Intermediates for the preparation of modulators of toll-like receptors